Catheter Precision (VTAK) Common Equity (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Common Equity data on file, last reported at $9.6 million in Q1 2026.

• Quarterly Common Equity rose 20.88% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 20.88% YoY) and the FY2025 annual result came in at $6.7 million, down 43.43% from the prior year.
• Common Equity advanced to $9.6 million in Q1 2026 per VTAK's latest filing, from $6.7 million in the prior quarter.
• Across five years, Common Equity topped out at $35.9 million in Q1 2023 and bottomed at $6.4 million in Q3 2025.
• The 5-year median for Common Equity is $12.5 million (2022), against an average of $14.5 million.
• The widest annual swing landed in 2023, when Common Equity surged 142.99%; it then tumbled 57.27% in 2025.
• Tracing VTAK's Common Equity over 5 years: stood at $9.3 million in 2022, then soared by 128.87% to $21.2 million in 2023, then sank by 44.52% to $11.8 million in 2024, then plunged by 43.43% to $6.7 million in 2025, then soared by 43.87% to $9.6 million in 2026.
• Per Business Quant, the three latest VTAK Common Equity figures stand at $9.6 million (Q1 2026), $6.7 million (Q4 2025), and $6.4 million (Q3 2025).

Peer Comparison